CRYOLIFE, ENDOLOGIX ENTER INTO AGREEMENT FOR BIOFOAM

CryoLife and Endologix have entered into a development and marketing agreement for the percutaneous or endovascular delivery of CryoLife's BioFoam as a self-expanding sealant for endovascular aortic aneurysm grafts.

BioFoam, a protein hydrogel adhesive currently in preclinical development, contains an expansion agent which has the potential to rapidly fill and seal internal body cavities, such as aneurysm sacs, and provide hemostasis in penetrating wounds and severe trauma.

The product is based on CryoLife's BioGlue, already FDA-approved to control bleeding as an adjunct to sutures and staples in the open surgical repair of large blood vessels.

Under the agreement, Endologix will be responsible for preclinical, clinical, and regulatory activities and costs, and CryoLife will manufacture BioFoam for clinical use and commercial sale and receive a royalty on potential future product sales.